. Author manuscript; available in PMC: 2020 Nov 1.

Published in final edited form as: Transplantation. 2020 May;104(5):1058–1069. doi: 10.1097/TP.0000000000002917

Table 1:

1-year results of the BEST trial shows higher rates of acute rejection and of increased histologic severity in BELA treated patients when compared to TAC treated patients but without adverse effects on graft function.

	Group A	Group B	Group C	p- value Group A vs Group C	p- value Group B vs Group C
Patients analyzed	105	102	105
Induction	alemtuzumab	rATG	rATG
Immunosuppression	BELA	BELA	Tac
BPAR (%)	18 (17.1)	20 (19.6)	5(4.08)	0.014	0.003
1^st BPACR Grade ≥ 2a	5 (4.8)	8 (7.8)	0	0.12	0.009

rATG, rabbit anti-thymocyte globulin; BELA, belatacept; Tac, tacrolimus; BPAR, biopsy proven acute rejection; BPACR, biopsy proven acute cellular rejection.